Oncimmune Holdings PLC Senior Leadership Team Appointments & Board Change (7292J)
December 06 2018 - 11:34AM
UK Regulatory
TIDMONC
RNS Number : 7292J
Oncimmune Holdings PLC
06 December 2018
6 December 2018
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Senior Leadership Team Appointments and Board Change
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
today announces the appointment to the Senior Leadership Team of
Matthew Hall as Group Chief Financial Officer and Andrew Stewart as
General Counsel and Company Secretary.
Andrew Millet has stepped down from the Board as Chief Financial
Officer, Director and Company Secretary. Andrew will be available
to the Company for the next six months to ensure an orderly
transition of his CFO responsibilities.
Matthew Hall is a seasoned finance professional with over 25
years' of corporate finance experience in a number of leading
organisations and fast-growing companies. Most recently he was
Chief Financial Officer at Tusk Therapeutics and Simbec-Orion
Group. Previously, Matthew was Chief Financial Officer at Sphere
Medical Holding plc where he was appointed to lead the company's
successful IPO and prior to that was Chief Financial Officer of IS
Pharma plc, where he was closely involved in the merger of IS
Pharma plc and Sinclair Pharma plc. Matthew is a Chartered
Accountant with a degree in Economics.
Andrew Stewart is an international business lawyer with
extensive healthcare industry experience. Andrew's previous role
was at Smith & Nephew plc, where he was responsible for leading
the legal teams supporting the group's global M&A efforts and
European commercial operations. Before that, he was Chief Counsel,
Global Transactions and Corporate at Shire plc. Before joining
industry, Andrew spent a number of years in private legal practice,
primarily at Clifford Chance. Andrew has extensive experience
advising FTSE100 companies and multinationals and has held
executive leadership positions. He holds degrees in Law and Science
(Biochemistry and Immunology).
Dr Adam Hill, CEO of Oncimmune commented: "The additions to the
Senior Leadership Team we are announcing today will help me drive
the delivery of Oncimmune's strategy to capitalise on the wide
range of opportunities presented by our proprietary
autoantibody-based platform. Matthew and Andrew both have highly
relevant experience and will support the Board in its day-to-day
activities as we set about delivering the next chapter of our
Company's strategy over the next three years.
"I would like to thank Andrew Millet for his 15 years of service
to Oncimmune. Andrew has been instrumental in supporting
Oncimmune's journey to date, helping the Company through a step
change in process and reporting after Oncimmune's IPO in May 2016.
We wish him well for the future as he seeks to spend more time on
his portfolio of directorships and outside interests."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, John Goold
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Alix Mecklenburg-Solodkoff
+44 (0)20 3207 7800
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of personalised immunodiagnostics for the
screening, detection and care of cancer. Oncimmune is changing how
clinicians, researchers and patients view, diagnose and treat
cancer. Our technology detects evidence of the body's natural
response to cancer, enabling detection 4 years or more before
standard clinical diagnosis. Our tests facilitate clinical
decision-making and are complementary to diagnostic technologies,
making them valuable additions to established and new care
pathways. We partner with leading developers and distributors to
make our technology available globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT(R) -Lung and EarlyCDT(R) -Liver. To date, over 155,000
tests have been performed for patients worldwide and EarlyCDT(R)
-Lung is being used in the largest-ever randomised trial for the
early detection of lung cancer using biomarkers, the National
Health Service (NHS) ECLS study of 12,210 high-risk smokers in
Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA
lab in Kansas, US and offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOATFBFTMBJMBBP
(END) Dow Jones Newswires
December 06, 2018 11:34 ET (16:34 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024